Literature DB >> 18060632

Modulatory effects of EPA and DHA on proliferation and apoptosis of pancreatic cancer cells.

Weikang Zhang1, Yueping Long, Jinghui Zhang, Chunyou Wang.   

Abstract

In order to investigate the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on the proliferation, apoptosis of pancreatic cancer cell line SW1990 cells and the expression of cyclin E mRNA, the SW1990 cells were treated with different concentrations of EPA or DHA (20, 40, 60 microg/mL) for 0, 12, 24, 36 and 48 h respectively. By using MTT method, the inhibitory effects of EPA or DHA on the cell growth were assayed. Real time PCR was used to detect the expression changes of cyclin E mRNA after the SW1990 cells were treated with 40 microg/mL EPA or DHA for different time. Flow cytometry was used to test the changes of apoptostic rate in the SW1990 cells treated with different concentrations of EPA or DHA for 24 h. The results showed that EPA and DHA could inhibit the growth of SW1990 cells in a time-and concentration-dependent manner (P<0.01). EPA or DHA could also significantly inhibit the expression of cyclin E mRNA in a time-dependent manner (P<0.05). EPA or DHA could induce the apoptosis of SW1990 cells in a concentration-dependent manner (P<0.01). It was concluded that omega-3 fatty acid could inhibit the proliferation of pancreatic cancer cell line SW1990 cells and promote their apoptosis. The down-regulation of the cyclin E expression by omega-3 fatty acid might be one of the mechanisms for its anti-tumor effect on pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18060632     DOI: 10.1007/s11596-007-0518-y

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  10 in total

Review 1.  Nutrition and cancer risk: an overview.

Authors:  Esteve Fernández; Silvano Gallus; Carlo La Vecchia
Journal:  J Br Menopause Soc       Date:  2006-12

2.  Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes.

Authors:  A S Lundberg; R A Weinberg
Journal:  Mol Cell Biol       Date:  1998-02       Impact factor: 4.272

3.  Cdc2-cyclin E complexes regulate the G1/S phase transition.

Authors:  Eiman Aleem; Hiroaki Kiyokawa; Philipp Kaldis
Journal:  Nat Cell Biol       Date:  2005-07-10       Impact factor: 28.824

4.  Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma.

Authors:  Daniel G Rosen; Gong Yang; Michael T Deavers; Anais Malpica; John J Kavanagh; Gordon B Mills; Jinsong Liu
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

5.  Cyclin E expression and outcome in pancreatic ductal adenocarcinoma.

Authors:  David A Skalicky; James G Kench; Davendra Segara; Maxwell J Coleman; Robert L Sutherland; Susan M Henshall; Elizabeth A Musgrove; Andrew V Biankin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-10       Impact factor: 4.254

6.  Phospholipid hydroperoxide glutathione peroxidase plays a role in protecting cancer cells from docosahexaenoic acid-induced cytotoxicity.

Authors:  Wei-Qun Ding; Stuart E Lind
Journal:  Mol Cancer Ther       Date:  2007-04       Impact factor: 6.261

7.  Promotive effects of hyperthermia on the inhibition of DNA synthesis in ehrlich ascites tumor cells by eicosapentaenoic and docosahexaenoic acids.

Authors:  H Tanaka; K Kageyama; M Kimura; S I Iwamoto; Y Ueno; K Asagi; R Asada; N Miwa
Journal:  Exp Oncol       Date:  2006-09

8.  Conjugated docosahexaenoic acid is a potent inducer of cell cycle arrest and apoptosis and inhibits growth of colo 201 human colon cancer cells.

Authors:  Naoyuki Danbara; Takashi Yuri; Miki Tsujita-Kyutoku; Mutsuya Sato; Hideto Senzaki; Hideho Takada; Takahiko Hada; Teruo Miyazawa; Kazuichi Okazaki; Airo Tsubura
Journal:  Nutr Cancer       Date:  2004       Impact factor: 2.900

Review 9.  (n-3) fatty acids and cancer therapy.

Authors:  W Elaine Hardman
Journal:  J Nutr       Date:  2004-12       Impact factor: 4.798

10.  Perioperative administration of parenteral fish oil supplements in a routine clinical setting improves patient outcome after major abdominal surgery.

Authors:  Evangelos Tsekos; Clemens Reuter; Peter Stehle; Gerhard Boeden
Journal:  Clin Nutr       Date:  2004-06       Impact factor: 7.324

  10 in total
  5 in total

1.  Effect of ω-3 polyunsaturated fatty acid on toll-like receptors in patients with severe multiple trauma.

Authors:  Chengzhi Yi; Xiangjun Bai; Jige Chen; Jiajun Chen; Jian Li; Peng Liu; Yiliu Liao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-08-07

Review 2.  Anti-cancer Mechanism of Docosahexaenoic Acid in Pancreatic Carcinogenesis: A Mini-review.

Authors:  Mirae Park; Hyeyoung Kim
Journal:  J Cancer Prev       Date:  2017-03-30

3.  Omega-3 Fatty Acids Prevent Early Pancreatic Carcinogenesis via Repression of the AKT Pathway.

Authors:  Yongzeng Ding; Bhargava Mullapudi; Carolina Torres; Emman Mascariñas; Georgina Mancinelli; Andrew M Diaz; Ronald McKinney; Morgan Barron; Michelle Schultz; Michael Heiferman; Mireille Wojtanek; Kevin Adrian; Brian DeCant; Sambasiva Rao; Michel Ouellette; Ming-Sound Tsao; David J Bentrem; Paul J Grippo
Journal:  Nutrients       Date:  2018-09-12       Impact factor: 5.717

4.  Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3.

Authors:  John Isherwood; Ali Arshad; Wen Yuan Chung; Franscois Runau; Jill Cooke; Cristina Pollard; Lynne Howells; Jenny Fishwick; John Thompson; Matthew Metcalfe; William Steward; Ashley Dennison
Journal:  Ann Transl Med       Date:  2020-03

5.  Eicosapentaenoic Acid Inhibits KRAS Mutant Pancreatic Cancer Cell Growth by Suppressing Hepassocin Expression and STAT3 Phosphorylation.

Authors:  Ching-Feng Chiu; Ming-I Hsu; Hsiu-Yen Yeh; Ji Min Park; Yu-Shiuan Shen; Te-Hsuan Tung; Jun-Jie Huang; Hung-Tsung Wu; Shih-Yi Huang
Journal:  Biomolecules       Date:  2021-03-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.